Schedule 13G ownership disclosure

ASPIRE BIOPHARMA HLDGS INC

Common Stock · CUSIP: 738920107

Event date: 2025-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Ardsley Advisory Partners LP

    Shares: 10,750,000.00 · Class: 7.76%

  • Ardsley Advisory Partners GP LLC

    Shares: 10,750,000.00 · Class: 7.76%

  • Ardsley Partners I GP LLC

    Shares: 10,750,000.00 · Class: 7.76%

  • Ardsley Partners Advanced Healthcare Fund, L.P.

    Shares: 9,229,100.00 · Class: 6.67%

  • Ardsley Partners Fund II, L.P.

    Shares: 1,520,900.00 · Class: 1.10%

  • Philip J. Hempleman

    Shares: 10,750,000.00 · Class: 7.76%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001213900-26-015382
Form type
SCHEDULE 13G
Filer
ARDSLEY ADVISORY PARTNERS LP
CIK
CIK 900529
Filed
Feb 12, 2026
Reporting period
Dec 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub